EDAP TMS SA, a developer of the most advanced and clinically proven choice for high-intensity focused ultrasound treatment of localized prostate cancer, recently announced that the company has signed an exclusive agreement with Lumenis, GmbH, one of the world’s largest medical laser companies.
Under the terms of the agreement, EDAP will distribute Lumenis urological Holmium/Nd:YAG lasers in France, effective immediately. This exclusive distribution agreement will allow EDAP to broaden its products portfolio by offering urologists a high-end therapeutic option for their patients. Lumenis lasers enable precise minimally invasive treatment for a wide variety of urologic conditions and the company has strong knowledge of the French urology market and French urologists.
Marc Oczachowski, chief executive officer of EDAP, stated, “I am very enthusiastic about adding Lumenis lasers, recognized as top ranked urology lasers, to our product offering in France. For years, EDAP has proven its leadership and track record in selling urological medical devices in France. In addition to representing a new revenue opportunity, the distribution of Lumenis’ lasers in France will reinforce EDAP’s presence in the urological field by further positioning us as one of the major players offering a wide range of minimally-invasive technologies to patients with urological conditions.”
Lloyd Diamond, president of Lumenis, added, “We are pleased to enter into this distribution agreement with EDAP. The French urology market is important to Lumenis and we now have the best partner to develop and support it. The combination of EDAP and Lumenis products provides a comprehensive solution to many of the urologists’ stone and prostate needs.”
For more information on EDAP, please visit www.edap-tms.com.
For more information about Lumenis and its products, please visit www.lumenis.com